Principles and Challenges in anti-COVID-19 Vaccine Development
- 28 February 2021
- journal article
- review article
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 182 (4), 339-349
- https://doi.org/10.1159/000514225
Abstract
The number of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected patients keeps rising in most of the European countries despite the pandemic precaution measures. The current antiviral and anti-inflammatory therapeutic approaches are only supportive, have limited efficacy, and the prevention in reducing the transmission of SARS-CoV-2 virus is the best hope for public health. It is presumed that an effective vaccination against SARS-CoV-2 infection could mobilize the innate and adaptive immune responses and provide a protection against severe forms of coronavirus disease 2019 (COVID-19) disease. As the race for the effective and safe vaccine has begun, different strategies were introduced. To date, viral vector-based vaccines, genetic vaccines, attenuated vaccines, and protein-based vaccines are the major vaccine types tested in the clinical trials. Over 80 clinical trials have been initiated; however, only 18 vaccines have reached the clinical phase II/III or III, and 4 vaccine candidates are under consideration or have been approved for the use so far. In addition, the protective effect of the off-target vaccines, such as Bacillus Calmette-Guerin and measles vaccine, is being explored in randomized prospective clinical trials with SARS-CoV-2-infected patients. In this review, we discuss the most promising anti-COVID-19 vaccine clinical trials and different vaccination strategies in order to provide more clarity into the ongoing clinical trials.Keywords
This publication has 101 references indexed in Scilit:
- Type I IFN Counteracts the Induction of Antigen-Specific Immune Responses by Lipid-Based Delivery of mRNA VaccinesMolecular Therapy, 2013
- The Double-Edged Sword: How Evolution Can Make or Break a Live-Attenuated Virus VaccineEvolution: Education and Outreach, 2011
- Randomized Trial of BCG Vaccination at Birth to Low-Birth-Weight Children: Beneficial Nonspecific Effects in the Neonatal Period?The Journal of Infectious Diseases, 2011
- Principles of vaccine design—Lessons from natureVaccine, 2010
- Rationalizing the development of live attenuated virus vaccinesNature Biotechnology, 2010
- Wanted, dead or alive: New viral vaccinesAntiviral Research, 2009
- Plants as bioreactors for the production of vaccine antigensBiotechnology Advances, 2009
- Selection of Molecular Structure and Delivery of RNA Oligonucleotides to Activate TLR7 versus TLR8 and to Induce High Amounts of IL-12p70 in Primary Human MonocytesThe Journal of Immunology, 2009
- Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus diseaseNature Medicine, 2008
- Measles antibody: comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virusVaccine, 1994